862P - Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Urothelial Cancers
Genitourinary Cancers
Presenter Alfonso Gomez de Liano Lista
Citation Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371
Authors A. Gomez de Liano Lista1, A. Necchi2, P. Lavaud3, J. Carles Galceran4, D. Castellano5, A. Ravaud6, I. Duran7, N. van Dijk8, P. Giannatempo2, Y. Loriot3, R. Morales Barrera9, G. De Velasco Oria De Rueda5, F. Lefort6, G. Martínez Bernal7, D. Raggi2, M. Gross-Goupil10, T. Powles1, M. Van der Heijden8
  • 1Oncology, St. Bartholomew's Hospital, EC1A 7BE - London/GB
  • 2Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 5Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 6Medical Oncology, Bordeaux University Hospital, 33000 - Bordeaux/FR
  • 7Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 8Medical Oncology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 9Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 10Medical Oncology, CHU Bordeaux Hopital St. André, 33000 - Bordeaux/FR



PD-1/PD-L1 inhibitors are changing the current landscape of mUC. Outcomes after discontinuation of ICI are unclear in this population.


Data from 8 European institutions was retrospectively collected. Target population was patients progressing on ICI. Univariate and multivariate analysis for overall survival (OS, calculated from the last date of ICI until death from any cause) as well as potential predictive factors of response to post-progression therapy (ppT) were performed. Tests were two-sided.


From March 2013 to April 2017, 291 patients were identified. 227 (78%) experienced progression (PD) on ICI. Median post-progression OS of ICI was 5 months (95% CI 3.7-6.3), being 8.6 (95%CI 7.5-9.7) if receiving ppT vs 1.8 (95%CI 1.5-2.1) if best supportive care alone (p 


Many patients do not receive subsequent chemotherapy, including CT-naive patients. Patients who receive post-ICI therapy have good outcomes. ICI does not appear to confer resistance to CT. Retrospective analysis is prone to bias.

Clinical trial identification

Legal entity responsible for the study

Alfonso Gómez de Liaño Lista




Y. Loriot: AstraZeneca, Roche, MSD, Pfizer, Astellas, Janssen, Clovis, Bristol-Myers Squib. T. Powles: Roche/Genentech, AstraZeneca, MSD. M. Van der Heijden: Roche/Genentech, AstraZeneca, Astellas, Bristol-Myers Squib, MSD. All other authors have declared no conflicts of interest.